NeuroGenesis develops pharmaceutical therapy using cell therapy to treat neurodegenerative diseases, such as MS and ALS. Currently, its treatment undergoes Phase 2 clinical trial.
Location: United States, New York, Rochester
Investors 1
| Date | Name | Website |
| - | Excell Par... | excellny.c... |
Mentions in press and media 5
| Date | Title | Description |
| 18.03.2026 | FDA Grants NeuroGenesis Bio RMAT Designation for NG01 for Treatment of Secondary Progressive Multiple Sclerosis | RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and improve function in patients with PMS. LAFAYETTE, CA, UNITED STATES, March 18, 2026 /EINPresswire.com/ -- NeuroGenesis Bio ... |
| 30.09.2025 | NeuroGenesis Announces Positive Phase 2 Extension Study Results of NG01 Cell Therapy in Progressive Multiple Sclerosis | Innovative therapies targeting the root causes of progressive multiple sclerosis and ALS. Study shows NG01 improved mobility, cognition, and quality of life, marking a step forward in treatment for progressive multiple sclerosis. Our missio... |
| 08.07.2025 | Promising New Data Shows Cellular Therapy Treatment from NeuroGenesis Significantly Improves Lifespan for ALS Patients | NeuroGenesis reveals positive survival outcomes in patients with ALS treated with “NG01”, a novel cell therapy in a new publication. This study provides compelling indications that NG01 therapies can extend survival in ALS patients, even th... |
| 08.05.2025 | NeuroGenesis Awarded Grant from National MS Society’s Fast Forward Program to Advance Cell Therapy & Phase IIb Trial | NeuroGenesis has been awarded a grant from the National MS Society to advance its NG01 cell therapy and launch its Phase IIb trial for secondary progressive MS. We are honored to receive this support from the National MS Society. NG01 has s... |
| 24.04.2023 | NeuroGenesis Receives FDA Clearance for Phase IIb Study | On the heels of Multiple Sclerosis (MS) Awareness Month, NeuroGenesis officially announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) to enroll patients in the U.S. for its Phas... |